Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Heterogeneity of global cancer outcomes

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.05.12
Views: 2851

Prof Reinhard Busse – Technische Universitat, Berlin, Germany

Prof Reinhard Busse talks to ecancer about the large variation in 5 year survival rates between countries in Europe at the European Forum on Oncology in Berlin, May 2012.


Prof Busse discusses the heterogeneity of cancer outcomes and the large discrepancies between countries, such as Norway and Ireland, whose five year survival rate in cervical cancer differs by 20%. Similar results are also seen in colon and breast cancer.


While cervical cancer now has a vaccine, data can only be observed retrospectively and results from the 1990s and mid-2000s show little to no change in survival and development of the disease. In breast and colon cancer, the development of the disease has reduced, but without a reduction in variations between countries.


Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation